News

Four organizations are teaming up with the goal of studying two neurodegenerative diseases — Parkinson’s disease and primary progressive multiple sclerosis — in space. Researchers from the Summit for Stem Cell Foundation labs in California and the New York Stem Cell Foundation Research Institute in New York…

When a person is awake, brain circuit activity is constantly “on.” This activity needs to be normalized during sleep. Researchers now report that neuronal activity in Parkinson’s disease patients with levodopa-induced dyskinesia fails to decrease during sleep. The study, “Levodopa-induced dyskinesia in Parkinson’s disease: sleep matters,” was published in…

A new method called DART ensures a compound injected into a region of the brain will affect only specific cell types. This approach was able to reverse Parkinson’s-related motor impairments in mice, and may hold the potential to provide more effective treatments. Although current research techniques such as gene editing and pharmacology…

Levodopa treatment can prevent movement impairment in patients with Parkinson’s disease by increasing overall sensory attenuation, or the ability to fine-tune information received from the senses before a motor action is performed, a study suggests. Based on these findings, researchers suggest that dopamine, which increases as a result of…

Rodin Therapeutics will evaluate a new imaging agent that allows the visualization of human synapses — the junctions between two nerve cells that allow them to communicate — in the living brain. Results from the study will guide the company’s upcoming Phase 1b trial of a new therapeutic compound designed to strengthen…

While attempting to transform a type of brain cell into neurons, researchers instead discovered they can turn mature neurons — which were previously believed to be unchangeable — into neurons that produce dopamine, the neurotransmitter that is lost in Parkinson’s disease. The incidental discovery has therapeutic implications for Parkinson’s and other…